Company news
Sinotherapeutics, Inc. news in 2025
Sinotherapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Announcement on Appointment of Senior Management Members
December 25, 2025
Announcement on Postponement of Investment Projects Financed by Raised Funds
December 12, 2025
Announcement on Voluntary Disclosure of the Renewal and Inclusion of the Company’s Product in the National Medical Insurance Catalog
December 8, 2025
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
November 4, 2025
Report for Q3 2025
October 30, 2025
Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Centralized Drug Procurement
October 29, 2025
Indicative Announcement on Equity Change of Shareholding Reduction by Shareholder with Over 5% Shares to Less than 5%
October 22, 2025
Announcement on Changing Signatory Certified Public Accountant
October 21, 2025
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Sitagliptin and Metformin Hydrochloride Sustained-release Tablets
October 20, 2025
Announcement on Release of Pledge of Partial Shares Held by Shareholders with Over 5% Shares
October 16, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
October 14, 2025
Announcement on Pledge of Partial Shares by Shareholders with Over 5% of Shares
October 10, 2025
Announcement on Increasing Estimated Amount of Daily Related Party Transactions in 2025
September 30, 2025
Announcement on Voluntary Disclosure of Obtaining Marketing Approval by the National Medical Products Administration for the New Strength of Sitagliptin and Metformin Hydrochloride Sustained-release Tablets
September 26, 2025
Announcement on Cancellation of Some Accounts for Raised Funds
September 23, 2025
Announcement on Attending Semi-annual Collective Performance Briefing for Enterprises in Biological Products and CXO Industries on SSE STAR Market 2025
September 5, 2025
Special Report on Semi-annual Deposit and Use of Raised Funds in 2025
August 22, 2025
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
August 17, 2025
Announcement on Using Partial Idle Raised Funds for Cash Management
August 8, 2025
Announcement on Voluntary Disclosure of Obtaining EU GMP Certification by the Wholly-owned Subsidiary
July 17, 2025
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Enzalutamide Tablets
June 26, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 22, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 29, 2025
Announcement on the Change of Investor Hotline
May 20, 2025
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets
May 12, 2025
Announcement on Changes in Some Directors, Senior Management Members, Financial Chief and Core Technical Personnel
May 5, 2025
Announcement on Canceling the Board of Supervisors and Amending the Articles of Association and Some Management Systems
April 29, 2025
Announcement on Pledge Release of Some Shares Held by Shareholders with Over 5% Shares
March 24, 2025
Announcement on Expiration of Plan of Shareholding Reduction by Shareholder with Over 5% Shares and Results of Shareholding Reduction
March 18, 2025
Indicative Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 1%
March 14, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 26, 2025
Announcement on the Estimated Routine Related Party Transactions for 2025
February 19, 2025
Announcement on Implementation Results of Shares Repurchase
February 18, 2025
Announcement on Progress in Repurchasing Shares
February 5, 2025
Annual Earnings Preannouncement for 2024
January 22, 2025